Bisoprolol (Monocor, Cyanamid; Emcor, Merck) is a new cardioselective β adrenoceptor blocking drug which is claimed to have “a distinctive pharmacokinetic and pharmacological profile, good efficacy and tolerance” and is “unlikely to adversely affect cardiovascular risk factors such as cholesterol”. Are these claims correct, and if so are they important clinically?
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.